Information  X 
Enter a valid email address

Allergy Therapeutics (AGY)

  Print   

Tuesday 23 November, 2021

Allergy Therapeutics

Result of AGM

RNS Number : 3040T
Allergy Therapeutics PLC
23 November 2021
 

 

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Result of Annual General Meeting

 

 

23 November 2021 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, with the exception of resolution 10, which failed to carry, all other resolutions proposed at the 2021 Annual General Meeting ("AGM") were duly passed by shareholders. Voting was conducted by way of a poll.  

 

Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and resolution 10 was proposed as a special resolution. The results of the poll are outlined in the table below.

 

The Board acknowledges the failure to pass resolution 10 and is disappointed in this outcome. The Board considers the flexibility afforded by these authorities to be in the best interests of the Company and shareholders and notes that this resolution has received support at previous AGMs. However, the Board remains committed to continuing an open and transparent dialogue and will, accordingly, seek to continue to engage with shareholders regarding their views in this area.

 

 

Resolution

For:

%age

Against:

%age

Withheld

1.  To receive a copy of the Annual Report for the year ended 30 June 2021

176,577,712

99.99

0

0

0

2. To approve the Directors' Remuneration Report

174,524,577

98.86

1,989,308

1.13

63,827

3. To re-appoint Mary Tavener as a Director 

176,161,541

99.98

7,089

0.01

409,082

4. To re-appoint Scott Leinenweber as a Director

173,381,457

98.41

2,787,173

1.58

409,082

5. To re-appoint Tunde Otulana as a Director 

176,161,541

99.98

7,089

0.01

409,082

6. To re-appoint Peter Jensen as a Director

173,387,212

98.84

2,022,948

1.15

1,167,552

7. To appoint BDO LLP as auditors of the Company

176,142,079

99.97

32,806

0.02

402,827

8. To authorise the Directors to determine the Auditors remuneration

176,577,712

99.99

0

0

0

9. To authorise the Directors to allot unissued share capital up to a specified amount (s551)

176,565,019

99.98

11,693

0.01

1,000

10 Special Resolution:

To disapply pre-emption provisions of s561(1) of the CoAct 2006 up to a specified amount

37,107,171

21.00

139,469,541

78.99

1,000

 

 

 

- ENDS -

 

For further information, please contact:

 

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

[email protected]

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

[email protected]

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFEEFEDEFSEIF

a d v e r t i s e m e n t